updated analysis of the observational GioTag study
Maximilian J Hochmair (Author),
Alessandro Morabito (Author),
Desiree Hao (Author),
Cheng-Ta Yang (Author),
Ross A Soo (Author),
James C-H Yang (Author),
Rasim Gucalp (Author),
Balazs Halmos (Author),
Lara Wang (Author),
Angela Märten (Author),
Tanja Čufer (Author)
Abstract
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.
Keywords
osimertinib;raziskava GioTag;GioTag study;
Data
Language: |
English |
Year of publishing: |
2019 |
Typology: |
1.01 - Original Scientific Article |
Publisher: |
Future Medicine Ltd |
UDC: |
616.2 |
COBISS: |
2048610929
|
ISSN: |
1744-8301 |
Views: |
917 |
Downloads: |
559 |
Average score: |
0 (0 votes) |
Metadata: |
|
Other data
Secondary keywords: |
Carcinoma, non-small cell lung;Therapy;Drug therapy;Afatinib;Nedrobnocelični karcinom pljuč;Terapija;Terapija z zdravili; |
Source comment: |
Nasl. z nasl. zaslona;
Soavtorica iz Slovenije: Tanja Cufer;
Opis vira z dne 10. 1. 2020;
|
Pages: |
str. 2905-2914 |
Volume: |
ǂVol. ǂ15 |
Issue: |
ǂiss. ǂ25 |
Chronology: |
Sep. 2019 |
DOI: |
10.2217/fon-2019-0346 |
ID: |
12014831 |